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Abstract
The current paradigm for elucidating the molecular etiology of cancers relies on the interrogation of small numbers of
genes, which limits the scope of investigation. Emerging second-generation massively parallel DNA sequencing
technologies have enabled more precise definition of the cancer genome on a global scale. We examined the genome
of a human primary malignant pleural mesothelioma (MPM) tumor and matched normal tissue by using a combination of
sequencing-by-synthesis and pyrosequencing methodologies to a 9.6X depth of coverage. Read density analysis uncovered
significant aneuploidy and numerous rearrangements. Method-dependent informatics rules, which combined the results of
different sequencing platforms, were developed to identify and validate candidate mutations of multiple types. Many more
tumor-specific rearrangements than point mutations were uncovered at this depth of sequencing, resulting in novel, large-
scale, inter- and intra-chromosomal deletions, inversions, and translocations. Nearly all candidate point mutations appeared
to be previously unknown SNPs. Thirty tumor-specific fusions/translocations were independently validated with PCR and
Sanger sequencing. Of these, 15 represented disrupted gene-encoding regions, including kinases, transcription factors, and
growth factors. One large deletion in DPP10 resulted in altered transcription and expression of DPP10 transcripts in a set of
53 additional MPM tumors correlated with survival. Additionally, three point mutations were observed in the coding regions
of NKX6-2, a transcription regulator, and NFRKB, a DNA-binding protein involved in modulating NFKB1. Several regions
containing genes such as PCBD2 and DHFR, which are involved in growth factor signaling and nucleotide synthesis,
respectively, were selectively amplified in the tumor. Second-generation sequencing uncovered all types of mutations in
this MPM tumor, with DNA rearrangements representing the dominant type.
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Introduction
Malignant pleural mesothelioma (MPM) is a highly aggressive
pleural tumor associated with asbestos exposure. Therapeutic
options are limited and median patient survival is about 7 months.
The standard chemotherapy regimen consisting of pemetrexed
and platinum extends median survival by approximately 2 months
[1]; however, select patients who undergo complete surgical
resection followed by chemotherapy and radiation derive a longer
survival benefit with some surviving over 5 years [2,3]. To date,
most clinical trials have focused on cytotoxic agents rather than
targeted therapies [4–6].
While it has been shown that chromosomal abnormalities are
abundant within MPM [7–11], whole genome analysis of this tumor
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10612has not yet been described. Massively parallel second-generation
sequencing methodologies using pyrosequencing or derivations of
sequencing by synthesis have paved the way for large-scale analyses
of tumor biology by targeted gene re-sequencing, mutation
detection, copy number variation (CNV), single nucleotide poly-
morphism (SNP), changes in chromatin architecture, and epigenetic
changes such as methylation pattern alteration [12–24]. The ability
to analyze entire genomes opens the door to global mapping of
normal variation and mutations of all types for correlation with
disease propensity, diagnosis, treatment, prognosis, as well as
identification of new targets for interventional therapy discovery
and development [15,25,26].
We report a definition at the genomic level of a primary human
MPM tumor using a combination of approaches, namely, Illumina
sequencing by synthesis and Roche/454 pyrosequencing [18,19,27].
Building upon previous work in which we sequenced the
transcriptomes of four MPM patient samples with Roche/454
technology [26], we selected the genomic DNA (gDNA) from a
tumor and normal control from one of those patients for more in-
depth analysis. In this single tumor, we found hundreds of previously
unreported single nucleotide variants (SNVs), single nucleotide
insertions/deletions (indels), inter- and intra-chromosomal large-scale
DNA rearrangements (including many that occur within genes), and
translocations. Many of the aberrations are tumor-specific mutations
occurring at loci that code for genes involved in distinct pathways
known to play key roles in cancer initiation and progression. We also
found substantial variability in this individual’s normal genome,
confirming previous reports [21,28–31]. The data herein suggest that
the numbers and types of variations both in the normal and the
MPM tumor genomes are considerable, and further, that efforts to
use these data (and similar data from other solid tumors) to elucidate
tumor biology and identify novel candidate therapeutic targets may
be more challenging than previously thought.
Results
Sequencing and mapping
We sequenced MPM tumor gDNA and matched normal lung
gDNA using Illumina paired-ends (PE) technology to generate 17.8
and 15.67 Gigabase pairs (Gbp) or 5.6X and 5.2X coverage of the
respective genomes (Table 1). Greater than 97% of the individual
sequenced reads aligned to NCBI’s RefSeq database. The tumor’s
read density when compared to the RefSeq database revealed
numerous chromosomal CNVs (Fig. 1), a known hallmark of many
tumor types including MPM [9,21,28,29,32–35]. Several chromo-
somes (2, 3, 6, 7, 10, 12, 13 and 20) appeared to be mostly euploid,
whereas others, including Y, 4, 14, 18, 19 and 10, were less abundant
than expected, or appeared to have extra copies (e.g., chromosome 5).
Furthermore, a number of chromosomes (1, 8, 9, 11, 15, 16, 17, 21,
and 22) appeared to have complex structures that included both
haploid and polyploid segments. The read density/CNV were
independently verified using deep exploration of the same samples
with comparative genomic hybridization (CGH) arrays (Fig. 2) and
were shown to match in a highly statistically significant manner
(Pearson correlation coefficient (r)=0.7918; 99% confidence interval
=0.788#r#0.796). Thus, whole genome sequence analysis revealed
as expected that this MPM tumor displayed large-scale aneuploidy.
Global validation using Roche/454 sequencing
Given the degree of aneuploidy and the large number of variants
observed with Illumina sequencing in both the tumor and normal
gDNAs, it became clear that independent validation or at least
prioritization of candidate tumor mutations would be required to
identify true positive mutations. Furthermore, second-generation
sequencing methodologies possess inherent limitations related to
artifacts and biases representing false-positive mutations [18,19,27,36].
Thus, a pyrosequencing approach (Roche/454) was undertaken to
confirm the read densities observed and the presence of any
mutations detected. Roche/454 sequencing of the tumor gDNA
generated 10.8 Gbp or ,4X coverage, extending the total coverage
of the tumor genome to nearly 10X. Ninety-six percent of the Roche/
454 reads mapped to known human DNA and the read density
analysis was highly statistically correlated with that obtained by
Illumina sequencing and the CGH arrays (Figs. 1 and 2 and File S1).
Genomic rearrangement
The dramatic changes in read density observed in the MPM
tumor (Figs. 1 and 2) led us to focus on the identification of
Table 1. Mapping of Illumina Paired-End Sequence Data.
Tumor Normal
Total reads (PE) 219,359,022 175,965,242
Total base pair 17,808,799,058 15,673,204,592
Avg. length/PE read 81 89
Mapping attributes of Paired-end
reads (Read 1: Read 2)
# of mapped reads %
# of mapped reads %
1:1 153,601,517 70.02% 131,604,101 74.79%
0:1 1,972,379 0.90% 1,435,061 0.82%
1:0 12,270,045 5.59% 4,109,024 2.34%
N:1 12,108,970 5.52% 9,250,544 5.26%
1:N 11,930,579 5.44% 8,867,264 5.04%
N:0 2,201,869 1.00% 705,230 0.40%
0:N 508,749 0.23% 357,149 0.20%
N:N 18,242,362 8.32% 14,769,141 8.39%
Total mapped reads 212,836,470 97.03% 171,097,514 97.23%
1, reads maps to unique region; 0, read does not map to any region; N, read maps to multiple regions.
doi:10.1371/journal.pone.0010612.t001
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which could represent inversions, deletions, insertions, and
translocations (File S2). For this analysis, the only variants that
were initially considered were those that were at least 1,000 bases
apart from expected using the normal genome sequence as a
reference. With Illumina data only, an analysis of all PE reads for
Figure 1. Sequence read mapping to the reference genome to display the Karyotype of the patient tumor and normal DNA by
Illumina and Roche/454 sequencing and by CGH.
doi:10.1371/journal.pone.0010612.g001
Figure 2. The read density of the long arm of chromosome 21 in tumor and normal with the validated rearrangements.
doi:10.1371/journal.pone.0010612.g002
Mesothelioma Genome Sequencing
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10612those not located in the expected proximity to each other revealed
423,310 candidate chromosomal rearrangements in the tumor and
443,087 in the normal sequences. However, only 2,432 rear-
rangements were common to the tumor and normal sequences, a
number more in-line with previous reports on variation in the
normal genome [21,28,37]. Furthermore, the number of rear-
rangements supported by increasing numbers of reads was much
lower, with only 485 in the tumor and 349 in the normal sequence
observed at a depth of $4 reads, for example. PCR validation of a
subset of rearrangements supported by fewer than 4 reads failed to
identify any true positives, suggesting that the majority of these
candidate rearrangements may be false positives possibly due to
artifacts of the technology [27,36,38] and/or mutations present in
a small number of tumor cells.
The Roche/454 method provided longer reads (,220 bp),
where a single read would be more likely to contain a
translocation-junction [18,19]. Similar to the findings above, the
number of candidate rearrangements was reduced to 1,524 at a
depth of 2 or more reads consistent with the hypothesis that
pyrosequencing may also produce artifactual rearrangements
[18,19,31].
We used two different approaches to prioritize for validation the
best candidates for true tumor-specific rearrangements. The first
approach enriched for chromosomal regions exhibiting read
density shifts. To find rearrangements, a combination of Roche/
454 and CGH data were used to identify junctions away from
areas of repeat sequences that were unique to the tumor,
particularly where the junctions were grossly apparent (e.g., Chr
21, Fig. 2). Using this approach, candidate Roche/454 rearrange-
ments were ranked for subsequent independent validation using
PCR and traditional Sanger sequencing. The top 33 candidate
rearrangements were validated by Sanger sequencing. Of these, 21
were found to be true mutations, i.e., present in tumor but not in
the matched normal gDNA, and 12 were present in both the
tumor and normal genomes consistent with polymorphisms. In the
second approach, the Illumina and Roche/454 data were
combined, and 105 tumor-specific rearrangements were observed
that were common to the two methods at a depth of at least 1 read
in each sequencing modality. These included 12 of the 21 tumor-
specific mutations validated as described above. The remaining 93
candidate rearrangements were examined further by Sanger
sequencing. Of these, 9 were tumor-specific mutations, 81 were
previously unknown variants present in both tumor and normal,
and 3 could not be confirmed. In total, 30 different tumor-specific
rearrangements were ultimately validated. Of these, 15 rearrange-
ments disrupted 17 genes (Table 2, Table S1, and File S2). Six of
the tumor-specific validated rearrangements were inter-chromo-
somal and 24 were intra-chromosomal. A set of 53 MPM tumors
was examined at the genomic level for all 30 tumor-specific
rearrangements using PCR amplification. None of these specific
rearrangements was found to be present in any additional tumor
genomes in the exact breakpoints discovered in our patient. One
of the rearrangements resulted in a large deletion within the
dipeptidyl-peptidase 10 (DPP10) gene (exons 4–25) and produced
the expected truncated fusion transcript uniquely in the tran-
scriptome of the tumor, but not of the normal lung.
The DPP10 gene was selected for further examination at the
transcriptome level in the additional 53 samples by using reverse
transcriptase-PCR (RT-PCR) assays. The presence/absence of the
DPP10 transcript was determined by targeting exon 2 and the
exon 2–3 junction. DPP10 transcript was detected in 31 of the 53
samples (55%). All of the 26 constituent exons were further
analyzed by RT-PCR in the 31 samples expressing DPP10.I n7o f
these samples, truncated DPP10 transcripts were identified, from
which we were either unable to amplify the region extending from
exon 26 to the 39 UTR (3 MPM samples), or found even shorter
transcripts (4 MPM samples). Additional analyses of these
transcripts are in progress.
Next, we investigated the correlation of DPP10 expression with
patient survival in the 53 samples tested. Surprisingly, we found
that patients with tumors expressing any DPP10 transcripts had
statistically significant better overall survival compared with
patients whose tumors lacked any DPP10 expression (22 months
versus 8 months median survival; P=0.004).
The Illumina data were also analyzed for rearrangements,
translocations, deletions, and inversions that were smaller than
1,000 bases and larger than 1 base. At a depth of at least 4 reads,
845 such rearrangements were identified of which 775 were
common to the tumor and normal gDNA, 19 were unique to the
normal, and 51 were unique to the tumor DNA representing
additional mutations.
Amplified rearrangements
Read densities from normal and tumor samples were compared
and 14 regions exhibiting rearrangements stood out as being
amplified in the tumor relative to the normal DNA by greater than
5X based on copy numbers. Of interest, over half of these regions
(9/14, 64%) included genes that are of known significance in
cancer such as the DHFR gene, whose product may confer
methotrexate resistance, and the PCBD2 gene, which is a co-factor
for TCF1 [39,40].
Single nucleotide variant (SNV) and indel variant
identification
To initiate the search for disease-associated variants, including
candidate somatic point mutations, SNVs were identified in tumor
and normal samples and characterized as known SNPs (i.e.,
present in dbSNP) or novel SNVs which would represent either
previously uncharacterized SNPs or mutations. With increasing
coverage, the percentage of known SNPs among the SNVs rose to
,95% suggesting that 4 to 5 reads may be sufficient for accurate
SNV determination with this technology and depth of coverage
(Table 3). Of interest, all four point mutations due to loss of
heterozygosity (LOH) discovered previously in the tumor tran-
scriptome of this patient [26] were also found to be present in the
tumor gDNA in the current study providing additional validation
of the approach. These mutations occurred in the coding regions
of AVEN, C9orf86, CTGLF6, and PSMD88P1/NOB1. These
observations, coupled with the fact that more than 90% of the
SNVs discovered here are present in dbSNP, support the use of
these sequencing data to identify heretofore unknown single base
alterations.
Candidate point mutation and indel identification by
combining sequencing technologies
The Roche/454 and Illumina SNV datasets were merged to
leverage the combined depth for prioritization of candidate point
mutations in coding sequences. There were 200,226 SNVs present
in both and absent from the Illumina normal sequence. Of these,
32,177 were new to dbSNP, 11,061 (33.4%) were present in
known genes, and 90 (0.81%) were within known exons of which
44 were non-synonymous. These 44 candidate mutations, as well
as 45 others present only in the Illumina tumor sequence at $2
coverage, new to dbSNP and within known genes, were
independently sequenced (Sanger) in the tumor and normal
samples. Of these, 83 were heterozygous novel SNPS, 3 were
homozygous in the tumor only, presumably due to LOH, and 3 in
Mesothelioma Genome Sequencing
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The NKX6-2 and NFRKB mutations were non-synonymous and
within coding exons. The CDH8 mutation was within an intron.
Similar patterns of variant prevalence were observed in the
analysis of single base indels. Illumina sequencing discovered
37,227 and 32,660 deletions in the tumor and normal specimens,
respectively, at a depth of 2 or more reads. Of these, only ,45%
were previously registered as known indels in dbSNP. Likewise,
36,326 and 31,116 single base insertions were observed in the
tumor and normal specimens, respectively, at a depth of 2 or more
reads, of which approximately 47% were previously known. When
combined at a coverage of $4 reads, there were 9,203 insertions
and 8,444 deletions common to both the tumor and normal
sequences of which ,53% were previously known. Of the 9,203
insertions, 3,795 occurred within genes and 5 occurred within
exons and could have functional consequences. Likewise, of the
8,444 deletions, 5,676 occurred within genes and 6 occurred
within exons. Similar results were observed in the Roche/454
data. Taken together, the results from indel analyses indicate that
the number of alterations of this type in the genome is substantially
smaller than that of single nucleotide alterations consistent with
previous reports [29].
Table 2. Rearrangement Mutations.
Chromosomal Break
Point (bp)
Chromosomal Break
Point (bp)
Gap Length
(bp) No. of Reads
Disrupted
Gene(s)
Break Point
Location in Gene(s)
Gene
Name/Function
Intrachromosomal
Chr2:115918613 Chr2:116314797 396183 4 DPP10 Exons 4–24 deleted K
+ Channel Modulator
Chr3:98917287 Chr3:99007383 90095 3 EPHA6 Intron 18 EPH receptor A6
Chr6:64615701 Chr6:57319605 7296095 1 EYS/PRIM2 Intron 36/Intron 5 Eyes shut homolog
(Drosophila)/Primase, DNA,
polypeptide 2 (58kDa)
Chr8:6749979 Chr8:34877265 28127285 1 None NA NA
Chr8:6786552 Chr8:34863640 28077087 3 None NA NA
Chr8:21254202 Chr8:72593210 51339007 1 None NA NA
Chr8:34816557 Chr8:72573255 37756697 1 None NA NA
Chr8:34816593 Chr8:72577581 37760987 3 None NA NA
Chr8:36550070 Chr8:72552661 36002590 3 None NA NA
Chr9:21957500 Chr9:22075035 117534 1 None NA NA
Chr10:84083200 Chr10:84157179 73978 1 NRG3 Intron 1/Inton 2 Neuregulin Growth Factor
Chr11:55762996 Chr11:55765854 2857 1 None NA NA
Chr11:59018943 Chr11:59023522 4578 1 None NA NA
Chr12:127300384 Chr12:126530113 770270 1 None NA NA
Chr17:23113949 Chr17:65721910 42607960 4 NOS2A Intron 22 Nitric Oxide Synthase
Chr17:26853914 Chr17:47815374 20961459 2 RAB11FIP4 Intron 3 Endosomal Trafficking
Chr17:47110011 Chr17:68044222 20934210 2 CA10 Intron 5 Carbonic Anhydrase
Chr17:65036914 Chr17:47505787 17531126 2 MAP2K6/CA10 Intron 10/Intron 2 Kinase Signaling to p38/
Carbonic Anhydrase
Chr17:47696961 Chr17:63830958 16133996 2 ARSG Intron 2 Arylsulfatase G
Chr19:38085640 Chr19:38091701 6060 1 CCDC123 Part of intron
14 deleted
Coiled-coil domain
Containing 123
Chr21:18540069 Chr21:33670572 15130502 2 CHODL Intron 1 Chondrolectin
Chr21:20864799 Chr21:18281613 2583185 4 None NA NA
Chr21:19693189 Chr21:31062421 11369231 2 None NA NA
Chr21:21167077 Chr21:27861346 6694268 1 None NA NA
Interchromosomal
Chr9:31759669 Chr11:84923849 1 DLG2 Intron 3 Disc Large Homologue 2
Chr10:117768069 Chr17:48272943 1 None NA NA
Chr10:121001050 Chr17:21238007 2 GRK5/KCNJ12 Intron 1/Intron 1 G-Protein Coupled Receptor/
Potassium Channel
Chr15:23876380 Chr6:67079455 1 None NA NA
Chr17:61459185 Chr21:21169765 1 CCDC46 Intron 12 Coiled-coil domain
containing 46
Chr21:35609289 Chr17:58726449 5 TANC2 Intron 7 Tetratricopeptide repeat,
ankyrin repeat and coiled-coil
containing 2
doi:10.1371/journal.pone.0010612.t002
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MPM specimens
In a follow-on analysis, we examined disrupted genes (n=15,
Table 2) and genes containing coding sequence point mutations
(NKX6-2, NFRKB) in previously published gene expression
microarray data from a total of 40 MPM patients [41]. Eleven
of these 17 genes were represented on the microarray: CA10,
CCDC46, CHODL, DLG2, GRK5, KCNJ12, MAP2K6, MTAP,
NFRKB, PRIM2, TANC2. Five of these 11 genes (CA10, CHODL,
DLG2, KCNJ12, TANC2) were not reliably detected (i.e., called
‘‘Absent’’ in all tumors). Five of the remaining 6 genes were
detected in a variable number of MPM tumors ranging from 45–
78% (gene, probe set, percent of samples called ‘‘Present’’):
CCDC46, 213644_at, 60%; GRK5, 204396_s_at, 55%; MAP2K6,
205698_s_at, 45%; NFRKB, 206968_s_at, 78%; PRIM2,
205628_at, 50%. The final gene (MTAP) was of particular interest
since it was represented by multiple probe sets which were
associated with discordant observations. MTAP was detected in
25% of MPM tumors using a probe set (204956_at) targeting the
39-UTR (GenBank Accession #NM_002451.3). Interestingly,
MTAP was also detected in 95% of MPM tumors using a probe
set (211364_at) specific to an alternatively spliced transcript
(GenBank Accession #AF109294.1) containing the first 4 exons of
MTAP (of 8 total coding region exons) joined to an additional 2
exons located ,25 Kb centromeric of CDKN2B. To be deter-
mined is whether the disruptions observed in these three genes in a
single patient in the current study can be linked to differential
expression patterns in additional MPM tumors.
Discussion
We leveraged a combination of two high-throughput next-
generation sequencing technologies to define the alterations that
occur at the nucleotide level in a single MPM tumor. The copy
number variations, the SNV profiles, as well as the many
rearrangements observed indicate that the number of alterations
in this single tumor is quite substantial both in terms of
polymorphism of the normal genome and in tumor-specific
mutations. At the depth sequenced here, many more rearrange-
ment type mutations than point mutations were identified and
validated. This finding, in combination with a previously known
propensity for aneuploidy in MPM, is consistent with the
hypothesis that MPM is more likely to be associated with larger-
scale chromosomal rearrangements than point mutations. This
might explain why specific oncogenes or tumor suppressors have
not yet been found for MPM. Obvious caveats are that this pilot
work focused on tumor from a single patient and that the depth of
sequencing may possibly be biased towards discovery of
rearrangement-type mutations. However, data from other re-
sequencing projects [42] as well as from our transcriptome
sequencing project [26] support the notion that some solid tumors
have fewer point mutations than others. Also consistent with
previous work is the observation that all four point mutations
previously discovered in the transcriptome of this tumor [26] were
due to a novel SNP present in one allele and a deletion in the
complementary allele.
Rearrangements, translocations, deletions, insertions, and
inversions have been associated with other cancers, particularly
leukemias and sarcomas. Specific rearrangements have been
clinically used for diagnosis and even to direct therapy as in the
case of the BCR-ABL fusion protein, the target of the drug
Gleevec [43,44]. Given that most of the rearrangements we
discovered involve chromosomes 8, 17, and 21, it is intriguing to
speculate that a similar phenomenon may occur in MPM. At the
very least, it highlights these areas of the genome as important for
additional study.
Rearrangements have been implicated in many other solid
cancers as well [35,43–46]. Thus, the potential roles of
rearrangements as oncogenic driver mutations and therapeutic
targets in the solid tumor genome may approach that of somatic
point mutations, at least for some tumors. However, unlike point
mutations, rearrangements have been difficult to define precisely
at the nucleotide level or to compare across many samples prior to
the advent of massively parallel sequencing approaches. There-
fore, the observations and the discovery methods developed herein
support a role and provide a strategy for direct unbiased genomic
sequencing for the precise identification, prioritization, and
validation of rearrangements in solid tumors.
Limitations associated with individual massively parallel se-
quencing technologies include sensitivity versus specificity, the
creation of artifacts, as well as the biases exhibited in certain
stretches. It has been previously reported that each of the
technologies used here has a large number of false positive
artifacts suggesting that stand alone methods may not be
sufficiently accurate to use independently for this purpose
[18,19,27,38]. Some biases that have been observed include the
propensity for errors in homopolymer stretches, under represen-
tation bias against A/T rich sequence regions, and creation of
rearrangement artifacts due to false primary priming during PCR
expansion [18,19,27]. While greater depth of sequencing and
innovative filtering techniques may improve upon some of the
limitations encountered in this analysis, artifacts inherent in the
Table 3. SNV Analysis.
Illumina Tumor* Illumina Normal* 454 Tumor*
Supporting Read(s) No of SNVs Known SNPs No of SNVs Known SNPs No of SNVs Known SNPs
Count % Count % Count %
=2 reads 599,783 508,936 84.85 624,928 548,185 87.72 929,217 629,043 67.70
=3 reads 347,027 317,641 91.53 330,330 305,757 92.56 463,075 355,305 76.73
=4 reads 198,605 185,383 93.34 164,700 154,985 94.10 243,543 189,916 77.98
=5 reads 109,543 103,455 94.44 76,707 72,825 94.94 126,668 96,046 75.82
=6 reads 57,509 54,671 95.07 34,417 32,772 95.22 66,129 47,581 71.95
=7 reads 29,960 28,588 95.42 14,758 13,947 94.50 36,329 23,620 65.02
*The depth is slightly different for each sequencing column accounting for differences in total SNVs.
doi:10.1371/journal.pone.0010612.t003
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sequencing. Therefore, the most powerful rationale for ruling in
alterations comes from a comparison and agreement of at least two
orthologous technologies. The need for the combination of two
different next-generation sequencing technologies is further
supported by the recent findings of Pleasance et al. who reported
deep sequencing of a small cell lung cancer cell line genome [47].
These investigators identified 134 coding exon somatic mutations
from among 22,910 somatic substitutions as well as 58 genomic
rearrangements. At this number of putative mutations, rapid
validation of all true mutations using traditional Sanger sequenc-
ing is not practical.
Although, clearly, more patient samples are needed to identify
the most frequent genomic alterations that play a functional role in
MPM, one may examine the data, postulate mechanisms of action,
and make inferences relative to putative pathways involved in
disease etiology. For example, many chemotherapeutic drugs are
largely ineffective in the treatment of MPM, including methotrex-
ate which targets the DHFR gene product [48]. The fact that there
is a substantial amplification of the DHFR locus in the tumor of this
chemotherapy naı ¨ve patient may explain why 80% of MPM
patients are resistant to methotrexate and similar drugs [4,6]. The
30 validated tumor specific rearrangements were directly within 17
genes and were just upstream from the promoters of 35 other
genes (see File S2), most of which have not been previously
described in cancer. However, several could plausibly be involved
in oncogenesis as they are known to affect receptor signaling, signal
transduction, cell proliferation, and apoptosis. Candidate genes for
further study include a growth factor (NRG3), two membrane
receptors (EPHA6 and GRK5), two signaling molecules (MAP2K6
and NOS2), a putative transcription factor (TANC2), as well as a
potassium channel protein and modulator (KCNJ12 and DPP10).
Particularly intriguing is the discovery that the absence of
DPP10 expression in MPM is associated with poor clinical
outcome, i.e., survival. DPP10 is located on the long arm of
chromosome 2 (2q12.3–2q14.2), close to DPP4 and FAP, and it
extends over 1 Mb of genomic DNA. In DPP10, the serine residue
critical to the active site of other DPP (dipeptidyl peptidase) family
members is replaced by a glycine residue, such that DPP10 lacks
dipeptidyl-peptidase activity [49,50]. DPP10 binds specific voltage-
gated potassium (K+) channels and alters their expression and
biophysical properties [51]. Alternate transcriptional DPP10 splice
variants, encoding 2 different isoforms (i.e., the ‘‘long’’ and ‘‘short’’
isoforms), have been partially characterized within NCBI’s RefSeq
database. In all the MPM samples expressing DPP10, only the
short isoform has been detected (data not shown). Northern Blot
analysis revealed strong DPP10 expression in brain, pancreas,
spinal cord, and adrenal glands. Less expression was found in
placenta, liver, and airways (trachea). Although Northern Blot
analysis did not show DPP10 expression, RT-PCR detected low
DPP10 expression in lung [49,50].
It is unknown what functional role DPP10 might play in MPM
tumor cells, but if it modulates K+ channel function it could
conceivably influence tumor cell survival or growth, as K+
channels are known in general to play important roles in
regulating cell proliferation, cell cycle progression, and apoptosis
[49,50]. DPP10 has also been linked to asthma by several
association studies of linkage and fine mapping [52]. In addition,
DPP10 is part of the ‘‘DPP-IV activity and/or structure
homologues’’ (DASH) molecules, which have deregulated expres-
sion in multiple human cancers determining their pathobiological
relevance in carcinogenesis.
Given the variable expression patterns, known and inferred
physiological functions, and likely role of MAP2K6, CCD46, and
MTAP in tumor cells, it is a priority to determine whether the
differential microarray gene expression patterns that were
observed in a larger number (n=40) of additional MPM samples
can be replicated in additional samples and linked to any of the
genomic disruptions observed in the current study. Specifically, we
are testing the hypothesis that MPM samples lacking expression of
these genes harbor similar genomic disruptions. MAP2K6 is a
kinase that phosphorylates p38 leading to apoptosis. Hence, loss of
expression (i.e., function) would inhibit a cell death signaling
mechanism. Given the level of aneuploidy in the MPM tumor, a
mutation resulting in a Chr17:21 translocation that interrupted
CCDC46 was notable. This gene product is likely involved in DNA
replication/repair based on conserved protein domain analysis
[53,54], and a lack of expression would likely promote
tumorigenesis. In addition, mutations in this family of genes are
known to be associated with gross chromosomal aberrations such
as those evident in many MPM tumors, including the sample
analyzed in this study. This mutation could potentially represent a
driver mutation for the tumor given the incidence of rearrange-
ment mutations [44]. Finally, the function and physiological role
(if any) of MTAP alternatively spliced transcript is unknown, but it
is frequently deleted in many types of cancer [55] making its
presence in 95% of MPMs (i.e., 38/40 tumors) an intriguing
avenue for additional exploration.
In addition to rearrangements, we discovered three novel point
mutations in three different genes (NKX6-2, CDH8, NFRKB).
NKX6-2 is a transcription factor with known positive and negative
regulatory activities in development and differentiation [56] and
has been postulated to be a tumor suppressor for some types of
brain tumors (e.g., oligodendrogliomas) [57]. CDH8 codes for
cadherin, part of an integral membrane protein family affecting
calcium-dependent cell adhesion. Inappropriate CDH8 expression
has been linked to a subset of renal cell carcinomas [58]. NFRKB
codes for a DNA-binding protein that interacts with NFKB1 and is
a candidate oncogene currently being evaluated in hematologic
and solid tumors [59,60].
This analysis demonstrates that there are many major, tumor-
specific chromosomal rearrangements in this single MPM tumor
and that clues discovered in the sequence of one tumor can lead to
the discovery of genes that might be inactivated in other ways in
related tumors. Ultimately, functional analysis, deeper sequencing,
and genotyping in additional specimens will be required to identify
true driver mutations in MPM and better define specific targets for
therapy. We find that comparison of tumor to normal sequences
for each case and using a second sequencing strategy, at least at
the validation phase, are essential given the large number of
polymorphisms and sequencing artifacts observed in MPM. Even
now, the cost of sequencing and bioinformatics analysis such as
described herein is too costly for widespread clinical application.
However, third generation sequencing technologies are becoming
available at more affordable prices. We envision that within the
next few years the high-throughput analysis of multiple cancer
genomes will become a reality and ultimately part of the clinical
diagnostic pipeline.
Methods
(Also see Materials and Methods S1, Materials and Methods S2,
and Table S2.)
Tumor Specimen and Sequencing
High quality, tumor enriched (.83%) gDNA was prepared
from frozen tissue tumor sections of a mixed histology MPM
tumor resected from a male patient using microaliquoting
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lung of the same individual. (Additional tumor specimens used for
validation purposes were obtained from the tumor bank at our
institution.) All human tissues were acquired under informed
written consent from a patient undergoing definitive surgery for
mesothelioma at Brigham and Women’s Hospital in Boston, MA.
All work was performed with protocol permission and under the
guidelines of the Institutional Review Boards at Brigham and
Women’s Hospital and the Dana-Farber Cancer Institute.
Sequencing data were deposited at GeneBank: GenomeProject
ID #41515.
For Illumina sequencing, gDNA was sequenced using the
Illumina Genome Analyzer 2 (GA2). PE reads of base pair (bp)
lengths 50 bp (4.6 Gbp), 45 bp (4.4 Gbp), and 36 bp (8.8 Gbp)
were generated from 5 runs on GA2 which produced 17.8 Gbp of
tumor genomic sequences. A further 4 runs of normal gDNA of
the same patient were used to generate reads of 50 bp (10.6 Gbp)
and 36 bp (5 Gbp), totaling 15.67 Gbp of genomic sequence data
[19].
For Roche/454 sequencing, tumor gDNA was also sequenced
using the Roche/454 GS20 Sequencing
TM System (Roche
Applied Sciences, Indianapolis, IN) to generate 47,359,608
sequence reads with an average length of 228 bp, comprising a
total of 10.8 Gbp [19].
Sequence filtering criteria and mapping
All PE reads from the Illumina and reads from the Roche/454
were filtered using the criteria of average read quality score (QS)
$20. Duplicate identical reads were discarded. PE reads that
passed filtering criteria were mapped individually to RefSeq
Human Genome V36.3 using Synamatix’s SynaAlign program
with a mapping threshold of 230 and mapping margin 0, which
allowed up to 3 mismatches and up to 2 opening gaps. A
maximum of 10 alignments were reported for each hit and the
Percentage Identity (PID) filter was set at $94%. The sample-
specific mapping results were paired using Read ID tags. Reads
belonging to the same PE shared the same unique read ID. From
these pairings, mapping results were segregated into four distinct
groups. These groups were labeled as: 1:1 where both reads
mapped uniquely against the human genome; 1:N where the first
read mapped uniquely while the second read either hit nil or
multiple sequences (hence inclusive of 1:0); N:1 where the second
read mapped uniquely while the first read either hit nil or multiple
sequences (hence inclusive of 0:1); and N:N where both reads
mapped to multiple sequences. The unique reads were defined as
all pairs of reads belonging to the groups of 1;1, 0:1, 1:0. The main
aim of this round of mapping was to further filter out potential
repeats from the unique reads by using a more stringent set of
parameters: Mapping threshold 227, Margin 0, Gap open 12,
Gap extent 5 with mismatch penalty 10, Max number of N:12,
and Maximum alignments per read 10. The pairing process was
repeated for a second round and the mapping results were
segregated into the same four groups as described above. Reads
that passed the second stage mapping were compiled into
‘RowFormat’ files and used for the detection of rearrangement
and SNVs, and for read density analysis. Alignment of Roche/454
DNA read sequences to an unmasked Human reference genome
(Build 36.3) used SynaSearch (Synamatix), a BLAST-like align-
ment tool, with a seed size of 15 base pairs. The seeding process
excludes seeds over-represented in the reference genome by a
factor of 6.0 or more and also requires multiple nearby seeds to
align before triggering detailed alignment with a dynamic
programming algorithm.
Comparative genomic hybridization (CGH)
CGH was performed comparing the tumor and normal control
specimens using the Nimblegen (Roche/Nimblegen Systems,
Madison, WI) Homo Sapien 8 array Whole Genome Tiling set.
This was HG18 build, NCBI 36, with probe length of 50–75 and
median probe spacing of 713 bp. The informatic analysis was
performed by Nimblegen using the segment algorithm to
determine changes in copy number [62].
The Pearson product-moment correlation coefficient was used
to analyze the strength and direction of the linear relationship
between CGH and PE tumor densities. A strong correlation
coefficient (between 0.7–1.0) denotes a strong linear relationship
between both CGH and sequence read density whereby
duplications and deletions are common in both. A positive
coefficient indicates that the increasing and decreasing trends
corresponded in both CGH and sequence read density, and vice
versa. The analysis was computed for all chromosomes as a whole.
The 99% confidence interval denotes the probability that a
Pearson correlation coefficient would fall out of the interval is 1%.
Copy number and read density analysis
Read densities for each of the Illumina tumor and normal
sequences were calculated from the number of accumulated reads
in a bin. Mapping hits were treated both as single ends: 1:N, N:1,
N:N and as paired-ends: 1:1, 1:N, N:1, N:N. Similarly for 454
sequence, read density was calculated from the accumulated reads
in a bin. Since 454 reads were not paired-end, mapping hits were
used in the calculation. A bin size of 1000 bp was used in the
calculation, and display of read density. The hit probability for a
repeat hit was calculated before it was added to the respective read
density bin. Read density charts based on the above criteria were
compiled for both normal (Illumina only) and tumor (both
Illumina and 454) reads, respectively. They were plotted as read
density with respect to chromosomal location and according to
individual chromosomes. From the read density charts, abrupt
changes (also termed ‘edges’) of read density can easily be
visualized and thus detected. The main aim was to detect copy
number variations (CNVs) in the read density profiles and to
compare and contrast these findings between the samples and
sequencing platforms. To identify rearrangements and transloca-
tions, CNVs along the length of each chromosome were analyzed,
by using the read density charts for the tumor sample, and
compared to the CGH plots, to the normal gDNA sequences, and
to the reference genomes for each chromosome.
SNV detection
Only unique filtered high quality PE reads where both ends
fulfilled the following conditions were retained for SNV analysis:
average QS of $20; and a PID $94. Three types of SNVs were
detected: single base substitution and insertion or deletion of a
single base, hereafter referred to as SNPs or indels. Any SNVs
detected at query positions 1 or $31 of the read were discarded
because of the high probability of base-calling errors at these
positions. A subsequent filtering was performed using the best QS
and supporting reads of a SNV. The rule used was SNVs with a
BQS ,23 and fewer than two supporting reads were discarded.
Unique hits of all 454 reads and top hits of 454 reads with multiple
alignments were channeled for SNV detection. These alignments
were further filtered and only alignments with $80% mapped
length, $20 average read QS, and $90% identity were processed
by the SNV pipeline. Again, three types of SNVs were detected
from these 454 tumor reads, i.e., SNVs and indels. All identified
SNVs were cross-checked against NCBI dbSNP (version number
B129).
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Illumina: 1:1, 1:N and N:1 PE reads that hit a repeat at one side
were used for rearrangement detection only if the next best hit had
a difference of $2 bases with best hit. In cases of multiple hits, only
the first and second best hits were compared. Rearrangement hits
obtained were further filtered to have an average QS of $20 and a
hit PID of $94%. Putative rearrangements were ranked according
to the number of supporting reads and whether they were located
near a read density change.
Roche/454: Read sequences in which a single read contained
two distinct and contiguous sequences that mapped to different
locations in the human genome were selected. If the best
alignment to the read failed to align to 35 bp or more from the
39 end of the read or 45 bp or more from the 59 end of the read,
then the unaligned portion of the read was subject to a second,
more sensitive round of alignment against the Human reference
genome using SynaSearch with a seed length of 14 bp. If there was
a unique alignment to this portion of the read then the original
alignment and the new alignment formed a rearrangement pair.
The rearrangement pairs were then combined to find rearrange-
ment locations supported by more than one read. Many reads
were found near centromere and telomere repeats, especially when
the centromere sequence was not in the reference genome. These
were assumed to be the result of a centromeric sequence not in the
reference genome being aligned to a similar sequence that is in the
reference genome. To filter these we removed pairs which had
excessive reads at one or both sides (.40 reads) and where one
side of the rearrangement pair had 3 or more alternate paths or
graph edges leading from it.
Validation studies
Selected candidate mutations were further characterized using
PCR and conventional Sanger sequencing of PCR products from
tumor and blood gDNA. The PCR analysis for validation was
performed as described previously [26]. Analysis of DPP10
expression was conducted using standard RT-PCR and exon-
specific primers. To determine the presence or absence of DPP10
transcript, RT-PCR was performed targeting exon 2. The presence
of the transcript was confirmed using primers spanning the exon 2–3
junction. The 31 MPM samples showing DPP10 expression were
further analyzed using primers that amplify exons 3–8, 4–9, 5–10,
9–15, 13–19, 17–22, 20–26, and 20- 59UTR. In 7 samples, the
amplicons were not detected in some of the PCR reaction targeting
different regions of the 59-DPP10 transcript. These truncated
transcripts were further analyzed using additional primers. The
primers are listed in Table S2. Survival analysis of patients with
DPP10-expressing tumors was conducted using Kaplan-Meier
survival curves and the log-rank test for determination of statistically
significant differences (P,0.05). Affymetrix microarray gene expres-
sion data (U133A array) from a total of 40 MPM tumors [41] was
obtained from NCBI (GEO Accession #GSE2549).
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